DarioHealth Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DarioHealth Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $7.39M | Mar 25, 2019 |
| FY2018 | Dec 31, 2017 | $5.17M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $2.80M | Mar 19, 2018 |
| FY2016 | Dec 31, 2015 | $823.0K | Mar 22, 2017 |
| FY2015 | Dec 31, 2014 | $51.0K | Feb 8, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Mar 24, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.67M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $13.27M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $5.98M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $9.66M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.96M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $2.51M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.60M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.77M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $1.31M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($830.0K) | Mar 19, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.71M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($42.75M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($59.43M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($62.19M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($76.76M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($29.45M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($17.74M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($17.80M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($15.74M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($10.89M) | Mar 19, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.66M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($57.74M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($56.19M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($56.81M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($76.49M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($29.90M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($17.71M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($17.69M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($14.42M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($11.10M) | Mar 19, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.79M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $24.18M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $20.25M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $19.65M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $17.22M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $4.43M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $3.69M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $3.68M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $3.30M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $2.15M | Mar 19, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.94M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($38.56M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($30.38M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($47.85M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($50.41M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($17.74M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($15.73M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($11.47M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($10.62M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($8.38M) | Mar 19, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.0K | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $138.0K | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $584.0K | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $442.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $261.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $118.0K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $98.0K | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $71.0K | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $195.0K | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $808.0K | Mar 19, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.08M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $118.88M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $96.39M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $119.19M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $100.77M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $35.41M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $24.57M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $14.09M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $6.96M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $3.87M | Mar 19, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.92M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $72.02M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $58.14M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $80.00M | Mar 10, 2025 |
| FY2023 | Dec 31, 2021 | $85.55M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $28.15M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $18.89M | Mar 22, 2022 |
| FY2020 | Dec 31, 2018 | $8.93M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $3.94M | Mar 17, 2020 |
| FY2018 | Dec 31, 2016 | ($6.54M) | Mar 25, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.43M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $57.43M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $41.64M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $41.64M | Mar 10, 2025 |
| FY2022 | Dec 31, 2021 | $41.64M | Mar 9, 2023 |
| FY2022 | Dec 31, 2020 | $0 | Mar 9, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($452.08M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($390.34M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($349.36M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($285.85M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($222.01M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($143.25M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($110.15M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($89.25M) | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | ($70.96M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($54.96M) | Mar 19, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.80M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $27.76M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $36.80M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $49.36M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $35.81M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $28.59M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $20.40M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $11.00M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | $3.72M | Mar 25, 2019 |
| FY2018 | Dec 31, 2016 | $1.09M | Mar 25, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 12 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 1 | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 2 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 4 | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 4 | Mar 22, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 12 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 1 | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 2 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 4 | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 4 | Mar 22, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.91M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 1.92M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 27.19M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 25.72M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 16.57M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 8.12M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 2.24M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 1.83M | Mar 17, 2020 |
| FY2018 | Dec 31, 2017 | 14.07M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | 5.71M | Mar 19, 2018 |